Skip to main content

Trustees of Columbia University in the City of New York

13F filer · CIK 0001420995
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$468MU.S. long equity reported on 13F
Positions21 new · 1 closed
Net flow last quarter-$555MBuys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 20262 positions
SPYSPDR S&P 500 ETF Trust$462M98.73%Not reported-54.8%Q4 2024
CBRSCerebras Systems Inc.$5.92M1.26%Not reportedNewQ2 2026
Q1 2026Reported May 15, 20262 positions
SPYSPDR S&P 500 ETF Trust$891M99.97%Not reported+13.0%Q4 2024
COHNCohen & Co Inc.$302K0.03%0.81%NewQ1 2026
Q4 2025Reported Feb 13, 20262 positions
SPYSPDR S&P 500 ETF Trust$826M99.60%Not reported+23.6%Q4 2024
FIGFigma, Inc.$430K0.05%Not reportedNewQ4 2025
Q3 2025Reported Nov 14, 20257 positions
SPYSPDR S&P 500 ETF Trust$653M99.69%Not reported-11.9%Q4 2024
SRZNSurrozen, Inc.$618K0.09%0.56%Not reportedQ3 2021
TNYATenaya Therapeutics, Inc.$473K0.07%0.18%Not reportedQ3 2021
QTTBQ32 Bio Inc.$265K0.04%1.09%Not reportedQ4 2024
RAPTRAPT Therapeutics, Inc.$237K0.04%0.06%Not reportedQ4 2020
VORVor Biopharma Inc.$224K0.03%0.05%0.0%Q1 2021
XLOXilio Therapeutics, Inc.$210K0.03%0.48%Not reportedQ4 2022
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.